Transplanting Embryonic Stem Cells Into The Eyes Of Patients With Macular Degeneration
Stem cell therapy is an area of research that is fast developing. This therapeutic method is slowly gaining traction. Thousands of patients with debilitating or terminal diseases are eagerly waiting for introduction of successful stem cell therapeutic techniques.
According to the Independent of UK, the US FDA has approved the controversial transplant of embryonic stem cells into the eyes of patients with Stargardt's macular degeneration. In this disease, the light-sensitive retina cells at the back of eye are destroyed.
The announcement follows the first injection of embryonic stem cells into a patient in the US who is partially paralysed as a result of a spinal cord injury. Last October, a US biotechnology company, Geron, announced the start of the first clinical trial of embryonic stem cells with the hope of repairing damaged nerves.
Geron is a Menlo Park, California based biotechnology company.
The first three patients will receive injections of 50,000 embryonic stem cells, the second set will receive 100,000 cells and the highest dose will be 200,000 cells.
Source: The Independent